Soleno Therapeutics Inc
NASDAQ:SLNO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
US |
|
Precia SA
PAR:PREC
|
FR |
|
W
|
Wuxi Paike New Materials Technology Co Ltd
SSE:605123
|
CN |
|
C
|
Coca-Cola Consolidated Inc
SWB:CC5
|
US |
|
Hong Lai Huat Group Ltd
SGX:CTO
|
SG |
|
Vanquis Banking Group PLC
LSE:VANQ
|
UK |
|
S
|
Shenzhen Dobot Corp Ltd
HKEX:2432
|
CN |
Soleno Therapeutics Inc
Soleno Therapeutics Inc. is a biopharmaceutical company centered on the pressing needs of rare disease patients, most notably those with Prader-Willi syndrome (PWS). This congenital condition, characterized by an insatiable appetite leading to chronic overeating and subsequent obesity, poses significant health risks. Soleno targets this niche through its pioneering drug candidate, DCCR (diazoxide choline controlled-release), which aims to regulate appetite and improve quality of life for PWS patients. By focusing its primary efforts on this orphan indication, Soleno seeks to capitalize on favorable regulatory designations and expedited pathways, affording them advantages in both development timelines and market exclusivity.
The company generates revenue through strategic partnerships, research grants, and potential future product sales, assuming regulatory approval of DCCR. One of their key strategies involves engaging with patient advocacy groups and the broader medical community to underscore the unmet needs in PWS and illustrate the potential of DCCR. Additionally, by exploring broader applications of their core technology, Soleno aims to diversify their pipeline, thus enhancing shareholder value and reinforcing their stronghold in the rare disease pharmaceutical sector. The company’s focus on innovation and collaboration, combined with a keen understanding of the regulatory landscape, positions it to navigate the complexities of biopharmaceutical market competition successfully.
Soleno Therapeutics Inc. is a biopharmaceutical company centered on the pressing needs of rare disease patients, most notably those with Prader-Willi syndrome (PWS). This congenital condition, characterized by an insatiable appetite leading to chronic overeating and subsequent obesity, poses significant health risks. Soleno targets this niche through its pioneering drug candidate, DCCR (diazoxide choline controlled-release), which aims to regulate appetite and improve quality of life for PWS patients. By focusing its primary efforts on this orphan indication, Soleno seeks to capitalize on favorable regulatory designations and expedited pathways, affording them advantages in both development timelines and market exclusivity.
The company generates revenue through strategic partnerships, research grants, and potential future product sales, assuming regulatory approval of DCCR. One of their key strategies involves engaging with patient advocacy groups and the broader medical community to underscore the unmet needs in PWS and illustrate the potential of DCCR. Additionally, by exploring broader applications of their core technology, Soleno aims to diversify their pipeline, thus enhancing shareholder value and reinforcing their stronghold in the rare disease pharmaceutical sector. The company’s focus on innovation and collaboration, combined with a keen understanding of the regulatory landscape, positions it to navigate the complexities of biopharmaceutical market competition successfully.
Blowout Q4 Revenue: Soleno delivered Q4 revenue of $91.7 million, nearly 40% higher than the previous quarter, and $190.4 million for the full year despite less than nine months of sales.
Profitability Achieved: The company reported positive full-year net income of $20.9 million and cash flow from operations of $48.7 million in Q4.
Strong Launch Momentum: Since VYKAT XR's launch, 1,250 patient start forms were received, representing 12.5% of the addressable U.S. market, with 859 active patients at year-end.
Durable Uptake & Adherence: VYKAT XR discontinuation rates remain low at about 12% due to adverse events and 15% overall, with high adherence and sustained refill rates.
Cash Position Bolstered: Soleno ended the year with $506.1 million in cash and securities, even after a $100 million share repurchase.
First-in-Class Medicine: VYKAT XR is the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome (PWS), with payers covering over 180 million lives.
EU Expansion Progress: European regulatory review is advancing, with a potential EMA decision expected around mid-2026, and commercialization plans underway.
Pipeline Growth: Soleno plans to expand VYKAT XR into new indications, beginning with glycogen storage disease type 1 (GSD1), with clinical development to start later in 2026.
